16 September 2026 editorial review · Item
Insulin degludec (Tresiba): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Insulin degludec (Tresiba)
Scope and findings:
- US label indication age 1+,42-hour clamp activity,25-hour half-life,3–4-day steady state and adult/pediatric dose-timing distinction verified. Removed absolute no-gap/no-stacking reassurance and categorical exercise dose advice. Global prices and comparative trial estimates not independently reverified.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.